What is Acute Lymphoblastic Leukemia?
Acute Lymphoblastic leukemia (ALL), is a cancer that starts from white blood cells called lymphocytes in the bone marrow (the soft inner part of the bones, where new blood cells are generated).
http://www.bmthospitalindia.com/Adult-Acute-Lymphoblastic-Leukemia.html
The 10th Annual Utah Health Services Research Conference: Gaps in Insurance Coverage for Pediatric Cancer Patients with Acute Lymphoblastic Leukemia. By: Rochelle Smits-Seemann, Ms; Aimee O. Hersh, MD; Mark N. Fluchel, MS; Kenneth M. Boucher, PhD; Anne C. Krichhoff, MPH, PhD
Patient Centered Research Methods Core, University of Utah, CCTS
Cancer Survivorship Care: Global Perspectives and Opportunities for Nurse-Le...Carevive
The 18th CNSA Annual Winter Congress, held Perth, Australia will featured On Q Health’s co-founder Dr. Carrie Stricker as a keynote speaker. The theme for this year’s edition is “Cancer Nursing: Expanding the Possibilities” and will focus on exploring the opportunities that exist in cancer nursing in 2015 and beyond.
What is Acute Lymphoblastic Leukemia?
Acute Lymphoblastic leukemia (ALL), is a cancer that starts from white blood cells called lymphocytes in the bone marrow (the soft inner part of the bones, where new blood cells are generated).
http://www.bmthospitalindia.com/Adult-Acute-Lymphoblastic-Leukemia.html
The 10th Annual Utah Health Services Research Conference: Gaps in Insurance Coverage for Pediatric Cancer Patients with Acute Lymphoblastic Leukemia. By: Rochelle Smits-Seemann, Ms; Aimee O. Hersh, MD; Mark N. Fluchel, MS; Kenneth M. Boucher, PhD; Anne C. Krichhoff, MPH, PhD
Patient Centered Research Methods Core, University of Utah, CCTS
Cancer Survivorship Care: Global Perspectives and Opportunities for Nurse-Le...Carevive
The 18th CNSA Annual Winter Congress, held Perth, Australia will featured On Q Health’s co-founder Dr. Carrie Stricker as a keynote speaker. The theme for this year’s edition is “Cancer Nursing: Expanding the Possibilities” and will focus on exploring the opportunities that exist in cancer nursing in 2015 and beyond.
The Future of the American Healthcare Delivery System in an Era of ChangePYA, P.C.
PYA Principal Dr. Kent Bottles, who is also PYA Analytics' Chief Medical Officer, gave the keynote address, "The Future of the American Healthcare Delivery System in an Era of Change at the Healthcare Business Intelligence Summit," September 19, 2013, in Minneapolis. Dr. Bottles discussed four key trends affecting the American healthcare delivery system: the Affordable Care Act (“ACA”), the digital revolution, big data, and social media. He examined how these trends together affect the way hospitals, providers, payers, employers, and government agencies adapt to the changing healthcare environment.
Advanced Laboratory Analytics — A Disruptive Solution for Health SystemsViewics
As US healthcare systems grapple with the recent upheavals in care payment and delivery, they are turning to advanced analytics as their “central nervous systems” for driving care and financial performance.
Laboratory information — spanning chemistry, pathology, microbiology and molecular testing, for example — is among the best sources of data for these advanced analytics, including clinician decision support, predictive analytics, population health management, and personalized medicine. When strategically harnessed and integrated to create a patient-centric lab data lake, laboratory information can form an affordable yet competitively powerful advanced analytics solution well suited for many health systems — i.e., a disruptive option.
L. Eleanor J. Herriman, MD, MBA, Chief Medical Informatics Officer of Viewics, explains why laboratory data should be a core strategic component for achieving success in value-based healthcare.
Transition to adult services - Gill Levitt
NHS Improving Quality held an event in London on 31 July 2013 to progress the children and young people transition to adult services work with a focus on turning the rhetoric into practice entitled “Working to Define a Generic Service Specification for Transition”
Adding Value to the EMR: A Clinical PerspectiveHealth Catalyst
Known for leading large-scale healthcare improvement using data and analytics to drive positive change, Dr. Charles Macias speaks to creating greater value in the EMR through analytics. This approach has done more to increase value than many other cost-reduction efforts.
In this webinar you will 1) Explore each component of the value equation, 2) learn how TCH has increased the value of its healthcare using data to drive quality an ever more important need of those facing capitated or value–based care reimbursements and 3) consider a new ROI equation for systems who have invested heavily in their EMRs
Empowering ACOs: Leveraging Quality Management Tools for MIPS and BeyondHealth Catalyst
Join us as we delve into the crucial realm of quality reporting for MSSP (Medicare Shared Savings Program) Accountable Care Organizations (ACOs).
In this session, we will explore how a robust quality management solution can empower your organization to meet regulatory requirements and improve processes for MIPS reporting and internal quality programs. Learn how our MeasureAble application enables compliance and fosters continuous improvement.
CRISPR-Cas9, a revolutionary gene-editing tool, holds immense potential to reshape medicine, agriculture, and our understanding of life. But like any powerful tool, it comes with ethical considerations.
Unveiling CRISPR: This naturally occurring bacterial defense system (crRNA & Cas9 protein) fights viruses. Scientists repurposed it for precise gene editing (correction, deletion, insertion) by targeting specific DNA sequences.
The Promise: CRISPR offers exciting possibilities:
Gene Therapy: Correcting genetic diseases like cystic fibrosis.
Agriculture: Engineering crops resistant to pests and harsh environments.
Research: Studying gene function to unlock new knowledge.
The Peril: Ethical concerns demand attention:
Off-target Effects: Unintended DNA edits can have unforeseen consequences.
Eugenics: Misusing CRISPR for designer babies raises social and ethical questions.
Equity: High costs could limit access to this potentially life-saving technology.
The Path Forward: Responsible development is crucial:
International Collaboration: Clear guidelines are needed for research and human trials.
Public Education: Open discussions ensure informed decisions about CRISPR.
Prioritize Safety and Ethics: Safety and ethical principles must be paramount.
CRISPR offers a powerful tool for a better future, but responsible development and addressing ethical concerns are essential. By prioritizing safety, fostering open dialogue, and ensuring equitable access, we can harness CRISPR's power for the benefit of all. (2998 characters)
Navigating Challenges: Mental Health, Legislation, and the Prison System in B...Guillermo Rivera
This conference will delve into the intricate intersections between mental health, legal frameworks, and the prison system in Bolivia. It aims to provide a comprehensive overview of the current challenges faced by mental health professionals working within the legislative and correctional landscapes. Topics of discussion will include the prevalence and impact of mental health issues among the incarcerated population, the effectiveness of existing mental health policies and legislation, and potential reforms to enhance the mental health support system within prisons.
Health Education on prevention of hypertensionRadhika kulvi
Hypertension is a chronic condition of concern due to its role in the causation of coronary heart diseases. Hypertension is a worldwide epidemic and important risk factor for coronary artery disease, stroke and renal diseases. Blood pressure is the force exerted by the blood against the walls of the blood vessels and is sufficient to maintain tissue perfusion during activity and rest. Hypertension is sustained elevation of BP. In adults, HTN exists when systolic blood pressure is equal to or greater than 140mmHg or diastolic BP is equal to or greater than 90mmHg. The
ICH Guidelines for Pharmacovigilance.pdfNEHA GUPTA
The "ICH Guidelines for Pharmacovigilance" PDF provides a comprehensive overview of the International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use (ICH) guidelines related to pharmacovigilance. These guidelines aim to ensure that drugs are safe and effective for patients by monitoring and assessing adverse effects, ensuring proper reporting systems, and improving risk management practices. The document is essential for professionals in the pharmaceutical industry, regulatory authorities, and healthcare providers, offering detailed procedures and standards for pharmacovigilance activities to enhance drug safety and protect public health.
The dimensions of healthcare quality refer to various attributes or aspects that define the standard of healthcare services. These dimensions are used to evaluate, measure, and improve the quality of care provided to patients. A comprehensive understanding of these dimensions ensures that healthcare systems can address various aspects of patient care effectively and holistically. Dimensions of Healthcare Quality and Performance of care include the following; Appropriateness, Availability, Competence, Continuity, Effectiveness, Efficiency, Efficacy, Prevention, Respect and Care, Safety as well as Timeliness.
CHAPTER 1 SEMESTER V - ROLE OF PEADIATRIC NURSE.pdfSachin Sharma
Pediatric nurses play a vital role in the health and well-being of children. Their responsibilities are wide-ranging, and their objectives can be categorized into several key areas:
1. Direct Patient Care:
Objective: Provide comprehensive and compassionate care to infants, children, and adolescents in various healthcare settings (hospitals, clinics, etc.).
This includes tasks like:
Monitoring vital signs and physical condition.
Administering medications and treatments.
Performing procedures as directed by doctors.
Assisting with daily living activities (bathing, feeding).
Providing emotional support and pain management.
2. Health Promotion and Education:
Objective: Promote healthy behaviors and educate children, families, and communities about preventive healthcare.
This includes tasks like:
Administering vaccinations.
Providing education on nutrition, hygiene, and development.
Offering breastfeeding and childbirth support.
Counseling families on safety and injury prevention.
3. Collaboration and Advocacy:
Objective: Collaborate effectively with doctors, social workers, therapists, and other healthcare professionals to ensure coordinated care for children.
Objective: Advocate for the rights and best interests of their patients, especially when children cannot speak for themselves.
This includes tasks like:
Communicating effectively with healthcare teams.
Identifying and addressing potential risks to child welfare.
Educating families about their child's condition and treatment options.
4. Professional Development and Research:
Objective: Stay up-to-date on the latest advancements in pediatric healthcare through continuing education and research.
Objective: Contribute to improving the quality of care for children by participating in research initiatives.
This includes tasks like:
Attending workshops and conferences on pediatric nursing.
Participating in clinical trials related to child health.
Implementing evidence-based practices into their daily routines.
By fulfilling these objectives, pediatric nurses play a crucial role in ensuring the optimal health and well-being of children throughout all stages of their development.
One of the most developed cities of India, the city of Chennai is the capital of Tamilnadu and many people from different parts of India come here to earn their bread and butter. Being a metropolitan, the city is filled with towering building and beaches but the sad part as with almost every Indian city
The Importance of Community Nursing Care.pdfAD Healthcare
NDIS and Community 24/7 Nursing Care is a specific type of support that may be provided under the NDIS for individuals with complex medical needs who require ongoing nursing care in a community setting, such as their home or a supported accommodation facility.
Contact ME {89011**83002} Haridwar ℂall Girls By Full Service Call Girl In Ha...
TREATMENT AND LONG-TERM COSTS OF PEDIATRIC ACUTE LYMPHOBLASTIC LEUKEMIA
1. TREATMENT AND LONG-TERM COSTS OF PEDIATRIC ACUTE
LYMPHOBLASTIC LEUKEMIA
9th ANNUAL UTAH HEALTH SERVICES RESEARCH CONFERENCE
April 30th, 2014
Sapna Kaul, PhD, MA
Post-Doctoral Research Associate, Health Economics
Hematology/Oncology, Department of Pediatrics
3. INTRODUCTION
• Why study pediatric cancer costs?
• Assess economic burden over time
• Cost effectiveness analyses
• Cost benefit analyses
• Cost containment techniques
• Costs of pediatric cancer is an understudies area.
• HCUP’s study on pediatric cancer hospitalizations, 2009.
• Russell et al. (2012, Pediatrics)
Systematic review of economic evaluations of pediatric cancer treatments.
Majority of the studies were by European investigators. Only 10 studies by U.S.
investigators.
Approaches to Value Based Care
4. WHY ACUTE LYMPHOBLASTIC LEUKEMIA (ALL)?
• Accounts for 25% to 30% of childhood cancer diagnoses.
• About 3,000 children and adolescents are diagnosed with ALL every year in the U.S.
• The incidence rate has gradually increased over time and survival rate 85% to 90%.
• Survival rates in Black and Hispanic children are lower than White children with ALL.
Blood Stem Cell
Lymphoid B Lymphocyte
T Lymphocyte
Myeloid
5. ALL TREATMENT
Induction
35 days
Post-Induction
Standard Risk = 9 months
High Risk = 7 months
Maintenance
Girls = 2 years
Boys= 3 years
Long-Term
> 5 years
Vary by risk and sex …
Standard risk – WBC count less than 50,000/μL and age 1 to younger than 10 years.
High risk – WBC count 50,000/μL or greater and/or age 10 years or older.
6. OBJECTIVES
• Examine hospitalizations costs of pediatric ALL over time.
- Aggregate costs.
- Disaggregate costs by cost components (room & care, diagnostics etc.) and
treatment phases (induction, post-induction, maintenance, long-term).
• Investigate factors that affect hospitalization costs.
‐ Treatment related factors (risk, relapse, infections etc.).
‐ Socio-economic factors (insurance, distance from hospital).
7. DATA
• N=553 pediatric ALL patients.
• Patients identified through the Intermountain Healthcare System.
• Diagnosed years 1998 to 2013.
• Longitudinal data – hospitalizations data with costs.
• Cost data adjusted for inflation using Consumer Price Index.
8. STATISTICAL METHODS
• Aggregate and disaggregate costs
-Annual average per patient hospitalization costs.
-Annual average costs by cost components and treatment phases.
• Factors that affect per patient hospitalization costs
- Multivariable regression – GLM.
- Separate regressions – within and after 5 years of diagnosis.
Analyses in STATA and R …..
9. Characteristics N %
Age at Diagnosis
(years)
< 1
1- 5
5 - 10
>10
19
306
100
128
3
55
18
23
Sex Female
Male
263
290
48
52
Race White
Non-White
484
69
87
12
Insurance at Diagnosis Public
Private
Uninsured
133
399
21
24
72
4
Residence at ALL Diagnosis UT
AZ, CO, ID, MT, NV,
WY
AK, CA, MO, WA
441
105
7
80
19
1
Patients Characteristics
10. Treatment Related Characteristics
ALL Specific Characteristics N %
ALL Risk
Infants
Standard Risk
High Risk
19
343
191
3
62
34
Phases for Standard and High Risk Patients
Induction
Post-Induction
Maintenance
Long-Term
521
376
337
99
97
72
60
19
ALL Relapse
Yes
No
63
490
11
89
Transplant
Yes
No
45
508
8
92
Mortality
Alive
Dead
490
63
89
11
- 97% patients were
diagnosed at Primary
Children’s Hospital
- Annual diagnoses
varied from 25 to 40
from 1998 to 2013
11. RESULTS
Aggregate Costs
2000 2005 2010
051015
Per Patient Per Hospitalization Average Annual Costs
Years
AverageCostsin$1000
Average Costs Per Hospitalization among ALL Patients
12. Disaggregated Costs by Cost Components
2000 2005 2010
02468
Per Patient Per Hospitalization Average Annual Costs
Years
AverageCostsin$1000
Room & Care
Therapy
Pharmacy
Diagnostic
Average Costs Per Hospitalization among ALL Patients
13. Disaggregated Costs by Treatment Phases
2000 2005 2010
05101520
Per Patient Per Hospitalization Average Annual Costs
Years
AverageCostsin$1000
Induction
Post-Induction
Maintenance
Long-Term
Average Costs Per Hospitalization among ALL Patients
14. Multivariable Regression Analysis for Treatment Costs within 5 years of Diagnosis
N=424, Hospitalizations=2887
Independent Variables Effect on Dependent
Variable
P-value
Treatment Related Characteristics
High Risk vs. Standard Risk 2298 <0.01
Relapse vs. no Relapse 3302 <0.01
Induction vs. Post-Induction 7160 <0.01
Infection vs. no Infection 1916 <0.05
Socio-Demographic Characteristics
Public vs. Private Insurance 1274 <0.01
Insignificant variables – race, sex, distance from facility etc. Controlled for fixed year effects.
Exclusions – infants, residents of WA, AK, MO, CA, and diagnosis after 2010.
15. Variable Effect on Dependent
Variable
P-value
Treatment Related Characteristics
Relapse vs. no Relapse 4355 <0.01
Infection vs. no
Infection
9884 <0.05
Socio-Demographic Characteristics
Uninsured vs. Private -3827 <0.05
N=99, Hospitalizations=237
Multivariable Regression Analysis for Long-Term Costs Starting 5 years after Diagnosis
The remaining variables were insignificant.
Exclusions – Residents of WA, AK, MO, CA.
16. CONCLUSIONS
• Average cost per hospitalization has increased over time. Increase differs
substantially by cost components and treatment phases.
• Factors that potentially increase costs:
• Treatment related and socio-demographic characteristics.
• Costs of treating infants very high – upper limit of $151,167 per visit.
• Value based care:
• Cost-effective patient-centered care for High Risk and Relapsed patients.
• Emphasis on managing induction, room and care, and pharmacy costs.
• Insurance can provide leads on monitoring high cost patients.
18. NEXT STEPS
• Use more refined treatment phase identifiers (e.g., LPs and pharmacy data).
• Incorporate physician costs and out-patient medical costs.
• Robust examination of late effects include patients diagnosed in 1980’s.
• Costs of all Pediatric cancers.
19. COLLABORATORS AND FUNDING
Anne C. Kirchhoff, PhD, MPH
Richard Lemons, MD
Kent Korgenski, MS
Mark Fluchel, MD
Anupam Verma, MD
Elizabeth Raetz, MD
Richard Nelson, PhD
Josh Schiffman, MD
Christi Ng, MPH
Seth Andrews, MBA
Funding Source: Primary Children’s Hospital’s Pediatric Cancer Program (PCHPCP)